CRISPR Repairs Cardiomyopathy ECGs in Mice 09/01/25

Welcome to Cardiology Today – Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals. Listen to This Episode Your browser does not support the audio element. Episode Summary This episode covers 8 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology. Featured Research Articles Article 1: Reticulated platelets in coronary artery disease: a multidimensional approach unveils prothrombotic signalling and novel therapeutic targets. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886063 Summary: This study characterizes hyperreactive reticulated platelets in CAD patients, identifying their prothrombotic molecular phenotype. The findings suggest that targeting these platelets could offer novel therapeutic strategies to improve outcomes in CAD patients. Article 2: Semaglutide promotes bone marrow-derived progenitor cell flux toward an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886061 Summary: The SEMA-VR CardioLink-15 trial demonstrates that semaglutide, a GLP-1RA, increases circulating vascular regenerative stem and progenitor cells. This suggests a potential mechanism by which semaglutide reduces cardiovascular events through promoting vessel repair and reducing atherothrombotic risk. Article 3: CRISPR activation to repair ECG abnormalities caused by a FLNC truncating variant in mice. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886060 Summary: This study demonstrates the potential of CRISPR activation to upregulate FLNC gene expression in mice with truncating variants, leading to repair of ECG abnormalities. This offers a promising gene-specific therapeutic strategy for FLNCtv-induced cardiomyopathy, for which no current targeted therapies exist. Article 4: Outcomes of cardiovascular screening in men aged 60-64 years: the DANCAVAS II trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884758 Summary: The DANCAVAS II trial evaluated population-based screening for cardiovascular disease in men aged 60-64. Results showed screening detected subclinical CVD but did not demonstrate significant all-cause mortality reduction within the trial’s timeframe. Article 5: Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884757 Summary: The ANDAMAN trial investigated twice-daily aspirin dosing in ACS patients with diabetes or suspected aspirin resistance. The study found that twice-daily aspirin did not reduce major adverse cardiovascular events compared to standard dosing in this high-risk population. Article 6: Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-Difference trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884558 Summary: The VICTORION-Difference trial demonstrates that inclisiran, a PCSK9 siRNA, effectively reduces LDL-C levels in patients with hypercholesterolemia when used as part of a combination treatment strategy. These findings support the use of inclisiran to achieve LDL-C goals and reduce atherosclerotic cardiovascular disease risk. Article 7: Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884439 Summary: This secondary analysis of the DAN-RSV trial examined the effectiveness of the RSVpreF vaccine in individuals with and without ASCVD. The study found no evidence that the vaccine reduces cardiovascular events in patients with pre-existing ASCVD, but did reduce respiratory illness. Article 8: High-dose vs. standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884413 Summary: standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial. This analysis of the DANFLU-2 trial compared high-dose versus standard-dose influenza vaccines in adults with and without ASCVD. The study found no significant difference in cardiovascular or respiratory outcomes between the two vaccine types, regardless of ASCVD status. Full Episode Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Reticulated platelets in coronary artery disease: a multidimensional approach unveils prothrombotic signalling and novel therapeutic targets. This study characterizes hyperreactive reticulated platelets in CAD patients, identifying their prothrombotic molecular phenotype. The findings suggest that targeting these platelets could offer novel therapeutic strategies to improve outcomes in CAD patients. Article number two. Semaglutide promotes bone marrow-derived progenitor cell flux toward an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial. The SEMA-VR CardioLink-15 trial demonstrates that semaglutide, a GLP-1RA, increases circulating vascular regenerative stem and progenitor cells. This suggests a potential mechanism by which semaglutide reduces cardiovascular events through promoting vessel repair and reducing atherothrombotic risk. Article number three. CRISPR activation to repair ECG abnormalities caused by a FLNC truncating variant in mice. This study demonstrates the potential of CRISPR activation to upregulate FLNC gene expression in mice with truncating variants, leading to repair of ECG abnormalities. This offers a promising gene-specific therapeutic strategy for FLNCtv-induced cardiomyopathy, for which no current targeted therapies exist. Article number four. Outcomes of cardiovascular screening in men aged 60-64 years: the DANCAVAS II trial. The DANCAVAS II trial evaluated population-based screening for cardiovascular disease in men aged 60-64. Results showed screening detected subclinical CVD but did not demonstrate significant all-cause mortality reduction within the trial’s timeframe. Article number five. Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial. The ANDAMAN trial investigated twice-daily aspirin dosing in ACS patients with diabetes or suspected aspirin resistance. The study found that twice-daily aspirin did not reduce major adverse cardiovascular events compared to standard dosing in this high-risk population. Article number six. Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-Difference trial. The VICTORION-Difference trial demonstrates that inclisiran, a PCSK9 siRNA, effectively reduces LDL-C levels in patients with hypercholesterolemia when used as part of a combination treatment strategy. These findings support the use of inclisiran to achieve LDL-C goals and reduce atherosclerotic cardiovascular disease risk. Article number seven. Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial. This secondary analysis of the DAN-RSV trial examined the effectiveness of the RSVpreF vaccine in individuals with and without ASCVD. The study found no evidence that the vaccine reduces cardiovascular events in patients with pre-existing ASCVD, but did reduce respiratory illness. Article number eight. High-dose vs. standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial. This analysis of the DANFLU-2 trial compared high-dose versus standard-dose influenza vaccines in adults with and without ASCVD. The study found no significant difference in cardiovascular or respiratory outcomes between the two vaccine types, regardless of ASCVD status. Thank you for listening to Cardiology Today. Keywords Medical Topics: Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine Journals: New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology About Cardiology Today Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care. Subscribe to stay updated with the latest cardiology research • Share with colleagues • Follow for more medical contentThe post CRISPR Repairs Cardiomyopathy ECGs in Mice 09/01/25 first appeared on Cardiology Today.